Tracing Your Family’s Roots May Soon Get A Lot More Expensive
Access to some genealogical records kept by the U.S. government may get a lot more expensive, especially for those seeking family records for immigrants from the late 1800s to mid-1900s.
Related Articles
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nature Medicine – In the final analysis of all cohorts in the phase 2 ROAR basket trial, dabrafenib plus trametinib exhibited tumor-agnostic clinical activity in…
FDA approves inavolisib with palbociclib and fulvestrant for endocrine
On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-
FDA approves inavolisib with palbociclib and fulvestrant for endocrine
On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-
FDA approves inavolisib with palbociclib and fulvestrant for endocrine
On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-
FDA approves inavolisib with palbociclib and fulvestrant for endocrine
On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-
FDA approves inavolisib with palbociclib and fulvestrant for endocrine
On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-
Vivek Subbiah: I have accepted the debate at the 2024 AACR Industry Roundtable – OncoDaily
Vivek Subbiah: I have accepted the debate at the 2024 AACR Industry Roundtable / AACR, AACR Roundtable, Alexander T. Pearson, American Association for Cancer
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with platinum/etoposide-based chemotherapy. Key molecular drivers include the inactivation of onco-suppressor genes…
Welcoming the future: embracing novel technologies for a progressive health system
Novel technologies offer great possibilities for improving patient care, but their adoption varies across different European countries. To successfully integrate these advancements, it is crucial…
Modernize Precision Oncology With Decentralized Trial Tools
This Viewpoint examines how modern precision oncology clinical trials, bolstered by decentralized trial tools, can enhance access to cancer treatments and reduce the burden of…